NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · IEX Real-Time Price · USD
21.99
+0.55 (2.57%)
At close: Apr 26, 2024, 4:00 PM
21.85
-0.14 (-0.64%)
After-hours: Apr 26, 2024, 6:25 PM EDT
NAMS Revenue
In the year 2023, NewAmsterdam Pharma Company had annual revenue of $15.66M, a decrease of -85.67%.
Revenue (ttm)
$15.66M
Revenue Growth
-85.67%
P/S Ratio
125.39
Revenue / Employee
$539,847
Employees
29
Market Cap
1.96B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 15.66M | -93.59M | -85.67% |
Dec 31, 2022 | 109.25M | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNAMS News
- 18 days ago - NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease - GlobeNewsWire
- 18 days ago - BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors - Business Wire
- 26 days ago - NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer - GlobeNewsWire
- 4 weeks ago - NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress - GlobeNewsWire
- 6 weeks ago - NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD - GlobeNewsWire
- 2 months ago - NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire